Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & ...

Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...

ICH E6 (R3) introduces a dedicated section on data governance, reflecting the increasing complexity of data sources and systems used in modern trials. Sponsors are expected to maintain oversight of ...

Both products can be used in the UK to provide protection against RSV disease in certain settings. Abrysvo was cleared for ...

AstraZeneca's new formulation of systemic lupus erythematosus (SLE) therapy Saphnelo has been turned down by the FDA, despite getting the go-ahead in Europe a few weeks ago.

Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.

Two months later, the institute launched the Standardized Organoid Modeling Center, a national initiative financed with an initial commitment of $87 million over three years, intended to improve the ...

Joenja is a sizeable contributor to Pharming's revenues, accounting for €38 million ($45 million) of its total sales of €70 ...

Venglustat is designed to reduce the toxic build-up, and the new trial showed that a daily dose of the drug achieved ...

Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US – a $3.5 ...

Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) could be just weeks away from having the first ...